Repligen Corporation

NasdaqGS RGEN

Repligen Corporation Market Capitalization on January 14, 2025: USD 8.77 B

Repligen Corporation Market Capitalization is USD 8.77 B on January 14, 2025, a -9.02% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Repligen Corporation 52-week high Market Capitalization is USD 11.63 B on February 16, 2024, which is 32.61% above the current Market Capitalization.
  • Repligen Corporation 52-week low Market Capitalization is USD 6.68 B on July 08, 2024, which is -23.78% below the current Market Capitalization.
  • Repligen Corporation average Market Capitalization for the last 52 weeks is USD 8.79 B.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
NasdaqGS: RGEN

Repligen Corporation

CEO Mr. Olivier Loeillot
IPO Date April 29, 1986
Location United States
Headquarters Building 1
Employees 1,783
Sector Health Care
Industries
Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Similar companies

HAE

Haemonetics Corporation

USD 79.96

0.69%

NVST

Envista Holdings Corp

USD 18.85

-0.74%

ATR

AptarGroup, Inc.

USD 154.61

0.47%

COO

The Cooper Companies, Inc.

USD 89.11

-2.38%

TFX

Teleflex Incorporated

USD 179.17

0.35%

WST

West Pharmaceutical Services, Inc.

USD 328.96

-3.13%

BDX

Becton, Dickinson and Company

USD 235.80

-0.17%

RMD

ResMed Inc.

USD 228.83

-0.62%

MMSI

Merit Medical Systems, Inc.

USD 99.89

4.44%

ICUI

ICU Medical, Inc.

USD 161.08

1.85%

HOLX

Hologic, Inc.

USD 70.20

-0.13%

ANGO

AngioDynamics, Inc.

USD 11.80

-5.30%

ISRG

Intuitive Surgical, Inc.

USD 538.88

-0.16%

StockViz Staff

January 15, 2025

Any question? Send us an email